The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Simone Biles was seen in an advertisement for the GLP-1 diabetes drug Mounjaro alongside her mother, Nellie Biles.

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Women's health doctor Ravina Bhanot, from Zonas Fertility, told LADbible: "Hair loss while taking Mounjaro is a common side effect due to rapid weight loss. It is more likely linked to caloric ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...